Contrast-enhanced magnetic resonance (MR) imaging has for years been the method of choice in the detection of metastatic brain tumors, and the twodimensional (2D) T1-weighted (T1W) spin-echo (SE) sequence has been the reference sequence in most institutions. However, at present, there are several competitors to T1W SE sequences. Since the introduction of magnetization-prepared rapid gradient echo (MP-RAGE), most published studies have compared the signal-to-noise and contrast-tonoise ratios of gray and white matter, or the diagnostic ability of various pathologies. Some previous studies with limited numbers of metastatic brain lesions have shown the superiority of contrast-enhanced MP-RAGE sequences compared to 2D T1W SE images in lesion detection (1, 2) . Several studies also exist in which contrast-enhanced fluid-attenuated inversion recovery (FLAIR) has been compared to T1W SE sequences to detect and delineate brain neoplasias and leptomeningeal disease (3, 4) . Diffusion-weighted MR imaging (DWI) can be used to characterize rather than detect brain metastasis, because DWI can provide information concerning the cellularity of the brain metastasis (5) .
MP-RAGE, a three-dimensional (3D) MR imaging sequence, yields high spatial resolution, allowing the precise assessment of brain diseases, including metastases. Another advantage of 3D MR imaging is that artifacts associated with blood flow are minimized. This is important in the posterior cranial fossa, where flow-related artifacts are not uncommon in contrast-enhanced 2D T1W SE imaging. Each sequence has its own advantages and disadvantages, and various improvements in sequences are still being made.
In this issue of Acta Radiologica, Kunieda et al. (6) report their experience on gadolinium-enhanced 3D MP-RAGE imaging of the brain. Their group prospectively compared the diagnostic ability of 3D MP-RAGE (slice thickness 1 mm) imaging in detecting metastatic brain tumors with that of 2D T1W SE imaging at 1.5T in 123 examinations from 92 patients with known malignancies. Gadopentetate dimeglumine was intravenously administered at a dose of 0.4 ml/kg body weight (maximum 20 ml). Four radiologists participated in the study. The results show that MP-RAGE imaging has significantly better detectability of brain metastatic lesions than 2D T1W SE imaging (PB0.05). There were significant differences in specificity (0.87 vs. 0.93), positive predictive value (0.86 vs. 0.92), and accuracy (0.78 vs. 0.84) between 2D MR and 3D MR imaging. Sensitivity (0.80 vs. 0.81) and negative predictive value (0.75 vs. 0.78) were equal. There were no statistically significant differences in the ability of each observer to detect brain metastases, regardless of their experience. Also, the image interpretation times were equal. The authors used 7-mm slices in transverse and coronal T1weighted SE series, which is a definitive drawback of this study. However, this well-conducted study by Kunieda et al. is recommended reading.
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